BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $XENE readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06922110-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~X-NOVA-OLE readout (P3) · Xenon Pharmaceuticals Inc. $XENE
DESCRIPTION:An Open-Label Study of Azetukalner in Major Depressive Disorder
 \n\nPrimary completion date: 2027-01 (estimated) — month only\, shown on
  the 1st\nPhase 3 · Neuro · Major Depressive Disorder\nEnrollment: 460 
 · Sites: 71\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT06922110\nhttps://clinicaltrials.gov/study/NCT0
 6922110
URL:https://datacutoff.com/radar.html?nct=NCT06922110
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667142-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~X-ACKT readout (P3) · Xenon Pharmaceuticals Inc. $XENE
DESCRIPTION:A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Ge
 neralized Tonic-Clonic Seizures\n\nPrimary completion date: 2027-04 (estim
 ated) — month only\, shown on the 1st\nOriginally planned: 2025-06 (+22.
 0 months)\nPhase 3 · Neuro · Primary Generalized Tonic-Clonic Seizures\n
 Enrollment: 160 · Sites: 141\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT05667142\nhttps://clinicaltria
 ls.gov/study/NCT05667142
URL:https://datacutoff.com/radar.html?nct=NCT05667142
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076407-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~X-NOVA3 readout (P3) · Xenon Pharmaceuticals Inc. $XENE
DESCRIPTION:A Randomized Study of Azetukalner Versus Placebo in Major Depre
 ssive Disorder (X-NOVA3)\n\nPrimary completion date: 2027-05 (estimated) 
 — month only\, shown on the 1st\nPhase 3 · Neuro · Major Depressive Di
 sorder\nEnrollment: 450 · Sites: 50\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07076407\nhttps://clini
 caltrials.gov/study/NCT07076407
URL:https://datacutoff.com/radar.html?nct=NCT07076407
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
